Metformin in Diabetic Patients with Heart Failure: Safe and Effective

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current Cardiovascular Risk Reports

• Publication date

  2013-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12170-013-0355-4PMID 24466358PMCID PMC3899937
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Supplemental Figure 1

  2014cited by this paper
• AMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer

  2013cited by this paper
• Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling.

  2013cited by this paper
• Economic Costs of Diabetes in the U.S. in 2012

  2013cited by this paper
• Myocardial ischemia-reperfusion injury: a neglected therapeutic target.

  2013cited by this paper
• Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure.

  2013cited by this paper
• Glucose Regulation of Load‐Induced mTOR Signaling and ER Stress in Mammalian Heart

  2013cited by this paper
• Cardioprotection techniques: preconditioning, postconditioning and remote conditioning (basic science).

  2013cited by this paper
• Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure: Systematic Review of Observational Studies Involving 34 000 Patients

  2013cited by this paper
• Metformin improves healthspan and lifespan in mice

  2013cited by this paper
• Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP

  2012cited by this paper
• Bariatric surgery to unload the stressed heart: a metabolic hypothesis.

  2012cited by this paper
• After avandia: the use of antidiabetic drugs in patients with heart failure.

  2012cited by this paper
• The effect of metformin on insulin resistance and exercise parameters in patients with heart failure

  2012cited by this paper
• Metformin Prevents the Development of Chronic Heart Failure in the SHHF Rat Model

  2012cited by this paper
• Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure.

  2011cited by this paper
• Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study

  2010cited by this paper
• Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

  2010cited by this paper
• Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure

  2010cited by this paper
• Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents.

  2010cited by this paper
• Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

  2010cited by this paper
• Insulin Sensitizers and Heart Failure: An Engine Flooded with Fuel

  2010cited by this paper
• Prevalence of Diabetes and High Risk for Diabetes Using A1C Criteria in the U.S. Population in 1988–2006

  2010cited by this paper
• The rise and fall of rosiglitazone.

  2010cited by this paper
• Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes.

  2010cited by this paper
• Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway.

  2010cited by this paper
• Intensive versus conventional glucose control in critically ill patients.

  2009cited by this paper
• Metformin Prevents Progression of Heart Failure in Dogs: Role of AMP-Activated Protein Kinase

  2009cited by this paper
• Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure

  2009cited by this paper
• Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.

  2008cited by this paper
• Diabetes, left ventricular systolic dysfunction, and chronic heart failure.

  2008cited by this paper
• Acute Metformin Therapy Confers Cardioprotection Against Myocardial Infarction Via AMPK-eNOS–Mediated Signaling

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Proposed Regulation of Gene Expression by Glucose in Rodent Heart

  2007cited by this paper
• Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Insulin resistance and risk of congestive heart failure.

  2005cited by this paper
• AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury.

  2004cited by this paper
• Diabetes and idiopathic cardiomyopathy: a nationwide case-control study.

  2003cited by this paper
• Economic costs of diabetes in the US in 2002.

  2003cited by this paper
• Metformin-associated lactic acidosis: case reports and literature review.

  2002cited by this paper
• Downregulation of Myocardial Myocyte Enhancer Factor 2C and Myocyte Enhancer Factor 2C-Regulated Gene Expression in Diabetic Patients With Nonischemic Heart Failure

  2002cited by this paper
• Adaptation and maladaptation of the heart in diabetes: Part I: general concepts.

  2002cited by this paper
• Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors.

  2001cited by this paper
• Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure.

  2001cited by this paper
• Glycemic Control and Heart Failure Among Adult Patients With Diabetes

  2001cited by this paper
• Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

  2000cited by this paper
• Thiazolidinediones for type 2 diabetes

  2000cited by this paper
• Impact of diabetes on cardiac structure and function: the strong heart study.

  2000cited by this paper
• Congestive Heart Failure: Fifty Years of Progress

  2000cited by this paper
• Heart failure: why and how to define it?

  1999cited by this paper
• Subcellular remodeling and heart dysfunction in chronic diabetes.

  1998cited by this paper
• Lactic acidosis in patients with diabetes treated with metformin.

  1998cited by this paper
• Contraindications to Metformin Therapy in Patients With NIDDM

  1997cited by this paper
• The myocardial and vascular pathology of diabetic cardiomyopathy.

  1996cited by this paper
• Myocardial alterations in diabetes and hypertension.

  1996cited by this paper
• Goodman and Gillman's The Pharmacological Basis of Therapeutics

  1992cited by this paper
• Goodman and Gilman's the Pharmacological Basis of Therapeutics

  1986cited by this paper
• Goodman & Gilman's The Pharmacological Basis of Therapeutics

  1985cited by this paper
• Lactic acidosis in biguanide-treated diabetics

  1978cited by this paper
• Role of diabetes in congestive heart failure: the Framingham study.

  1974cited by this paper

• More on the Magic of Metformin

  2023cites this paper
• Multimorbidity from Diabetes, Heart Failure, and Related Conditions: Assessing a Panel of Depressive Symptoms as Both Formative and Reflective Indicators of a Latent Trait

  2021cites this paper
• Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing

  2021cites this paper
• Heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus: pathophysiology and treatment options

  2021cites this paper
• Addressing Comorbidities in Heart Failure: Hypertension, Atrial Fibrillation, and Diabetes.

  2020cites this paper
• Ginsenoside Rb1 improved diabetic cardiomyopathy through regulating calcium signaling by alleviating protein O-GlcNAcylation.

  2019cites this paper
• Improvement of insulin signalling rescues inflammatory cardiac dysfunction

  2019cites this paper
• Clinical impact of oral antidiabetic medications in heart failure patients

  2018cites this paper
• Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management.

  2018cites this paper
• Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure

  2017cites this paper
• Metformin-like antidiabetic, cardio-protective and non-glycemic effects of naringenin: Molecular and pharmacological insights.

  2017cites this paper
• Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure

  2017cites this paper
• Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study

  2017cites this paper
• Metformina, el fármaco paradigma del siglo XXI

  2017cites this paper
• Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes

  2016cites this paper
• SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?

  2015cites this paper
• The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure

  2015cites this paper
• Remodeling of Glucose Metabolism Precedes Pressure Overload-Induced Left Ventricular Hypertrophy: Review of a Hypothesis

  2015cites this paper
• Metformin as a cellular protector; a synoptic view of modern evidences

  2015cites this paper